Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Standard
Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. / Schilling, Georgia; Hansen, Timon; Shimoni, A; Zabelina, Tatjana; Pérez-Simón, J-A; Simon-Perez, J-A; Gutierrez, N C; Fiedler, Walter; Liebisch, P; Schwerdtfeger, R; Bornhäuser, M; Otterstetter, S; Murga-Penas, Eva-Maria; Dierlamm, Judith; Ayuketang Ayuk, Francis; Atanackovic, Djordje; Bacher, Ulrike; Bokemeyer, Carsten; Zander, Axel R.; San Miguel, J; Miguel, J S; Nagler, A; Kröger, Nicolaus.
in: LEUKEMIA, Jahrgang 22, Nr. 6, 6, 2008, S. 1250-1255.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
AU - Schilling, Georgia
AU - Hansen, Timon
AU - Shimoni, A
AU - Zabelina, Tatjana
AU - Pérez-Simón, J-A
AU - Simon-Perez, J-A
AU - Gutierrez, N C
AU - Fiedler, Walter
AU - Liebisch, P
AU - Schwerdtfeger, R
AU - Bornhäuser, M
AU - Otterstetter, S
AU - Murga-Penas, Eva-Maria
AU - Dierlamm, Judith
AU - Ayuketang Ayuk, Francis
AU - Atanackovic, Djordje
AU - Bacher, Ulrike
AU - Bokemeyer, Carsten
AU - Zander, Axel R.
AU - San Miguel, J
AU - Miguel, J S
AU - Nagler, A
AU - Kröger, Nicolaus
PY - 2008
Y1 - 2008
N2 - We analyzed the prognostic impact of the most frequent genetic abnormalities detected by fluorescence in situ hybridization in 101 patients with multiple myeloma, who underwent allogeneic hematopoietic stem cell transplantation (HSCT) after melphalan/fludarabine-based reduced conditioning. The incidences of abnormalities in the present analysis were as follows: del(13q14) (61%), t(11;14)(q13;q32) (14%), t(4;14)(p16.3;q32) (19%), MYC-gain gains (8q24) (21%), del(17p13) (16%) and t(14;16)(q32;q23) (5%). None of the patients had t(6;14)(p25;q32). The overall complete remission (CR) rate was 50% with no differences between the genetic abnormalities except for patients with del(17p13) who achieved less CR (7 vs 56%; P=0.001). Univariate analysis revealed a higher relapse rate in patients aged >50 years (P=0.002), patients with del(13q14) (P=0.006) and patients with del(17p13) (P=0.003). In multivariate analyses, only del(13q14) (HR: 2.34, P=0.03) and del(17p13) (HR: 2.24; P=0.04) significantly influenced the incidence of relapse, whereas for event-free survival, only age (HR 2.8; P=0.01) and del(17p13) (HR: 2.05; P=0.03) retained their negative prognostic value. These data show that del(17p13) is a negative prognostic factor for achieving CR as well as for event-free survival after HSCT. Translocation t(4;14) might be overcome by allogeneic HSCT, which will have implication for risk-adapted strategies.
AB - We analyzed the prognostic impact of the most frequent genetic abnormalities detected by fluorescence in situ hybridization in 101 patients with multiple myeloma, who underwent allogeneic hematopoietic stem cell transplantation (HSCT) after melphalan/fludarabine-based reduced conditioning. The incidences of abnormalities in the present analysis were as follows: del(13q14) (61%), t(11;14)(q13;q32) (14%), t(4;14)(p16.3;q32) (19%), MYC-gain gains (8q24) (21%), del(17p13) (16%) and t(14;16)(q32;q23) (5%). None of the patients had t(6;14)(p25;q32). The overall complete remission (CR) rate was 50% with no differences between the genetic abnormalities except for patients with del(17p13) who achieved less CR (7 vs 56%; P=0.001). Univariate analysis revealed a higher relapse rate in patients aged >50 years (P=0.002), patients with del(13q14) (P=0.006) and patients with del(17p13) (P=0.003). In multivariate analyses, only del(13q14) (HR: 2.34, P=0.03) and del(17p13) (HR: 2.24; P=0.04) significantly influenced the incidence of relapse, whereas for event-free survival, only age (HR 2.8; P=0.01) and del(17p13) (HR: 2.05; P=0.03) retained their negative prognostic value. These data show that del(17p13) is a negative prognostic factor for achieving CR as well as for event-free survival after HSCT. Translocation t(4;14) might be overcome by allogeneic HSCT, which will have implication for risk-adapted strategies.
M3 - SCORING: Zeitschriftenaufsatz
VL - 22
SP - 1250
EP - 1255
JO - LEUKEMIA
JF - LEUKEMIA
SN - 0887-6924
IS - 6
M1 - 6
ER -